Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report
Pulmonary enteric adenocarcinoma (PEAC, also known as Enteric-type adenocarcinoma of the lung, lung - ETAC) is a rare subtype of non-small cell lung cancer (NSCLC) that has the same morphological and immunohistochemical characteristics as colorectal adenocarcinoma and requires gastroenteroscopy to r...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1509026/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591019716116480 |
|---|---|
| author | Ya Guo Bin Zhang Heng Zhang Yunbin Gao Haibo Zhao Pei Jiang Qing-Qing Yu |
| author_facet | Ya Guo Bin Zhang Heng Zhang Yunbin Gao Haibo Zhao Pei Jiang Qing-Qing Yu |
| author_sort | Ya Guo |
| collection | DOAJ |
| description | Pulmonary enteric adenocarcinoma (PEAC, also known as Enteric-type adenocarcinoma of the lung, lung - ETAC) is a rare subtype of non-small cell lung cancer (NSCLC) that has the same morphological and immunohistochemical characteristics as colorectal adenocarcinoma and requires gastroenteroscopy to rule out lesions of enteric origin. As a rare solid tumor in lung cancer, PEAC has unique clinical outcome, imaging, pathological and molecular characteristics, and poor prognosis. However, the molecular characteristics and therapeutic biomarkers of PEAC are unclear, and its treatment remains challenging. In this case, we describe a 61-year-old man diagnosed with advanced primary PEAC with KRAS mutation. In the case of unknown PD-L1 expression status, first-line treatment was given to lung adenocarcinoma regimen (immunotherapy combined with chemotherapy), progression occurred after 2 cycles, and progression-free survival (PFS) was 1.5 months. Then the second-line XELOX regimen (oxaliplatin combined with capecitabine) was adjusted. The lesions were significantly reduced after 2 and 4 cycles, and the disease progressed again after 6 cycles, with a PFS of 4.5 months. Anlotinib targeted drugs were selected for third-line treatment, but considering the overall poor condition of the patient, the patient himself refused further treatment. Finally, after discharge, the patient went to the local hospital for nutritional support and symptomatic treatment. The results suggest that standard first-line therapies (immunotherapy plus chemotherapy) and colorectal cancer regimens may have a relatively limited impact on survival in KRAS-driver positive advanced PEAC. |
| format | Article |
| id | doaj-art-34b5b03a010f4e3095023684575b1eab |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-34b5b03a010f4e3095023684575b1eab2025-01-23T05:10:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15090261509026Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case reportYa Guo0Bin Zhang1Heng Zhang2Yunbin Gao3Haibo Zhao4Pei Jiang5Qing-Qing Yu6Department of Oncology, Jining No.1 People’s Hospital, Jining, ChinaDepartment of Oncology, Jining No.1 People’s Hospital, Jining, ChinaRadiology Department, Jining No.1 People’s Hospital, Jining, ChinaDepartment of Oncology, Jining No.1 People’s Hospital, Jining, ChinaDepartment of Oncology, Jining No.1 People’s Hospital, Jining, ChinaTranslational Pharmaceutical Laboratory, Jining No.1 People’s Hospital, Jining, ChinaTranslational Pharmaceutical Laboratory, Jining No.1 People’s Hospital, Jining, ChinaPulmonary enteric adenocarcinoma (PEAC, also known as Enteric-type adenocarcinoma of the lung, lung - ETAC) is a rare subtype of non-small cell lung cancer (NSCLC) that has the same morphological and immunohistochemical characteristics as colorectal adenocarcinoma and requires gastroenteroscopy to rule out lesions of enteric origin. As a rare solid tumor in lung cancer, PEAC has unique clinical outcome, imaging, pathological and molecular characteristics, and poor prognosis. However, the molecular characteristics and therapeutic biomarkers of PEAC are unclear, and its treatment remains challenging. In this case, we describe a 61-year-old man diagnosed with advanced primary PEAC with KRAS mutation. In the case of unknown PD-L1 expression status, first-line treatment was given to lung adenocarcinoma regimen (immunotherapy combined with chemotherapy), progression occurred after 2 cycles, and progression-free survival (PFS) was 1.5 months. Then the second-line XELOX regimen (oxaliplatin combined with capecitabine) was adjusted. The lesions were significantly reduced after 2 and 4 cycles, and the disease progressed again after 6 cycles, with a PFS of 4.5 months. Anlotinib targeted drugs were selected for third-line treatment, but considering the overall poor condition of the patient, the patient himself refused further treatment. Finally, after discharge, the patient went to the local hospital for nutritional support and symptomatic treatment. The results suggest that standard first-line therapies (immunotherapy plus chemotherapy) and colorectal cancer regimens may have a relatively limited impact on survival in KRAS-driver positive advanced PEAC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1509026/fullpulmonary enteric adenocarcinomanon-small cell lung cancerdiagnosistreatmentprognosis |
| spellingShingle | Ya Guo Bin Zhang Heng Zhang Yunbin Gao Haibo Zhao Pei Jiang Qing-Qing Yu Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report Frontiers in Oncology pulmonary enteric adenocarcinoma non-small cell lung cancer diagnosis treatment prognosis |
| title | Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report |
| title_full | Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report |
| title_fullStr | Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report |
| title_full_unstemmed | Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report |
| title_short | Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report |
| title_sort | pulmonary enteric adenocarcinoma with progression disease after second line therapy a case report |
| topic | pulmonary enteric adenocarcinoma non-small cell lung cancer diagnosis treatment prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1509026/full |
| work_keys_str_mv | AT yaguo pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT binzhang pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT hengzhang pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT yunbingao pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT haibozhao pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT peijiang pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport AT qingqingyu pulmonaryentericadenocarcinomawithprogressiondiseaseaftersecondlinetherapyacasereport |